EGFR inhibitors

Taiho Pharmaceutical Acquires Cullinan Pearl, Regaining Rights to EGFR Inhibitor

Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce

Black Diamond Therapeutics Doses First Patient in Recurrent EGFR-Mutant Glioblastoma, NSCLC Trial

Blueprint Medicines Expands Trials of EGFR Inhibitors in NSCLC

FDA Approves FoundationOne CDx for EGFR Inhibitors to Identify EGFR Mutations in NSCLC

RedCloud Bio to Begin Trial of Fourth-Generation EGFR Inhibitor in NSCLC Subgroup

Cyclica, University of Toronto Lab Launch Joint Venture Perturba Therapeutics

Akeso Begins Phase III Trial of Bispecific Antibody, Chemo in EGFR-TKI Resistant NSCLC

Blueprint Medicines Acquires Lengo Therapeutics in $465M Deal

Hutchmed, AstraZeneca Begin Phase III Trial in NSCLC With EGFR, MET Mutations

Blueprint Medicines, Zai Lab Ink $615M Licensing Agreement for EGFR Inhibitors

SpringWorks Therapeutics Licenses EGFR Inhibitors From Dana-Farber, Inks Two R&D Partnerships

EQRx, NHS England Sign MOU to Facilitate Access to Cancer Drugs

ESMO Data Shed Light on Activity of Janssen's Rybrevant-Leclaza Combo in EGFR-Mutated NSCLC

Molecular Clonal Tracking Method Captures Lung Cancer Treatment Response, Resistance Features